EndoCell
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
EndoCell - overview
Established
2019
Location
Shanghai, -, China
Primary Industry
Biotechnology
About
Established in 2019 and based in Shanghai, China, EndoCell is a regenerative islet research and development company focuses on the in vitro regeneration technology of human tissues and organs. FounderXin Cheng is from the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences. In April 2025, the first product pipeline, allogeneic human regenerative islet injection (E-islet 01), acquired IND clinical approval from the National Medical Products Administration. In May 2025, it raised CNY 100 million in series A funding co-led by new investors Shanghai STVC Group and Lingang Digital Technology Fund.
The company's main product line is regenerative pancreatic islet transplantation. It also provides in vitro reconstruction of human tissues and organs. The company generates revenue by providing in vitro reconstructed pancreatic islet tissue. The company will use the funds to conduct Phase I/II clinical trials of its allogeneic universal regenerated islet pipeline, accelerate strategic deployment, and develop new pipelines for the treatment of diabetes and liver disease.
Current Investors
Kaitai Capital, Co-Power Venture Capital, Panlin Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Specialty Pharmaceuticals
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.